Tag: drug development
Sartar is strengthening its board of directors
Sartar Therapeutics is strengthening its board with two new board members, Jyrki Mattila and Jami Mandelin, who will bring decades of experience in the biotech industry and healthcare business to the company. Jyrki Mattila’s career in the pharma & biotech space spans for over forty years in Europe and in the U.S. Prior to moving to the […]
NOME Annual Meeting in Copenhagen on November 23rd 2021
Sartar participated the NOME Annual Meeting on 23rd Nov 2021 in Copenhagen, meeting mentors and other life science and medtech startups. NOME is an elite Nordic Mentoring Program that matches selected Nordic startups with highly skilled professionals to help them reach their goals and technology milestones. Sartar was selected to the program last June and has […]
Business Finland granted Sartar R&D Funding
We are proud to inform that the national innovation funding body Business Finland has granted R&D funding for Sartar Therapeutics. This R&D loan will allow us to advance the development of our product SAR001 towards clinical trials. We consider this positive decision as a significant credit for our technology for the treatment of soft tissue sarcomas.
Sartar’s therapy method featured in Drug Target Review
Targeting phosphodiesterase 3A: discovery of a promising cancer therapy in Drug Target Review describes the science behind Sartar’s new cancer therapy, outlining emerging evidence that PDE3A protein-targeting compounds may induce sarcoma cell death by acting as a molecular glue between PDE3A and Schlafen 12 proteins. Link to original article